v3.26.3
Consolidated Balance Sheets - USD ($)
$ in Millions
Sep. 30, 2026
Sep. 30, 2025
Current assets    
Cash and cash equivalents $ 480 $ 215
Accounts receivable, net - Notes A and H [1] 266 242
Inventories - Note A 482 568
Other assets 108 180
Total current assets 1,336 1,205
Property, plant and equipment - Note F    
Cost 3,304 3,355
Accumulated depreciation 2,170 2,154
Net property, plant and equipment 1,134 1,201
Goodwill - Note G [2] 698 705
Intangibles, net - Note G 498 563
Operating lease assets, net - Note J 99 103
Restricted investments - Note E 248 297
Asbestos insurance receivable, net - Notes A and M [3] 137 127
Deferred income taxes - Note K 138 157
Other assets - Note I 239 253
Total noncurrent assets 3,191 3,406
Total assets 4,527 4,611
Current liabilities    
Trade and other payables 210 189
Accrued expenses and other liabilities 220 213
Current portion of long-term debt - Note H 4 0
Current operating lease obligations - Note J 18 21
Total current liabilities 452 423
Noncurrent liabilities    
Long-term debt - Note H 1,367 1,384
Asbestos litigation reserves - Note M 385 389
Deferred income taxes - Note K 24 31
Employee benefit obligations - Note L 77 96
Operating lease obligations - Note J 83 85
Other liabilities - Note I 291 299
Total noncurrent liabilities 2,227 2,284
Commitments and contingencies - Notes J and M
Equity - Notes N and O    
Common stock, par value $.01 per share, 200 million shares authorized Issued 46 million shares in both 2026 and 2025 1 1
Paid-in capital 20 6
Retained earnings 2,225 2,298
Accumulated other comprehensive loss (398) (401)
Total equity 1,848 1,904
Total liabilities and equity $ 4,527 $ 4,611
[1] Accounts receivable, net includes an allowance for credit losses of $4 million and $2 million at September 30, 2026 and 2025, respectively.
[2] As of both September 30, 2026 and 2025, there were accumulated impairments of $375 million, $356 million, $505 million and $90 million related to the Life Sciences, Personal Care, Specialty Additives and Intermediates reportable segments, respectively.
[3] Asbestos insurance receivable, net includes an allowance for credit losses of $2 million at both September 30, 2026 and 2025.